343247-69-8

Basic information

• Product Name: 1-(4-chloro-3-(trifluoromethyl)phenyl)urea
• Synonyms: 1-(4-chloro-3-(trifluoromethyl)phenyl)urea;N-[4-Chloro-3-(trifluoromethyl)phenyl]urea;Sorafenib related coMpound 9;Sorafenib Impurity L;[4-chloro-3-(trifluoromethyl)phenyl]urea;Sorafenib Impurity 22
• CAS NO: 343247-69-8
• Molecular Formula: C₈H₆ClF₃N₂O
• Molecular Weight: 239
• EINECS: -0
• Mol File: 343247-69-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 275℃
• Flash Point: 120℃
• Appearance: /
• Density: 1.537
• CAS DataBase Reference: 1-(4-chloro-3-(trifluoromethyl)phenyl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-chloro-3-(trifluoromethyl)phenyl)urea(343247-69-8)
• EPA Substance Registry System: 1-(4-chloro-3-(trifluoromethyl)phenyl)urea(343247-69-8)

Safety Data

• Hazardous Substances Data: 343247-69-8(Hazardous Substances Data)

Usage

Uses

1-(4-Chloro-3-(trifluoromethyl)phenyl)urea is an impurity of Sorafenib (S676850); a multiple kinase inhibitor targeting both RAF and receptor tyrosine kinases that promote angiogenesis. Also antineoplastic.

Upstream product

• 917-61-3 sodium isocyanate 
• 320-51-4 4-chloro-3-trifluoromethyl-aniline 
• 445-01-2 5-bromo-2-chlorobenzotrifluoride 

Downstream Products

• 1129683-83-5 4-[ ({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenol 
• 284461-73-0 sorafenib 

Relevant articles and documents

Preparation method of sorafenib compound

The invention discloses a preparation method of a sorafenib compound. The preparation method comprises the following steps of: adopting reaction of 2-chloro-5-aminotrifluorotoluene and sodium cyanateto prepare a compound III, reaction of 4-bromophenol (compound IV) and a compound V to prepare a compound VI, and reaction of the compound VI and the compound III to obtain a final product, i.e., sorafenib (I). The preparation method disclosed by the invention has the beneficial effects that raw materials for reaction are low in cost and easy in obtaining, the process route is simple, the total yield is high, the side products are fewer, so that the preparation method is suitable for industrial production.

Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process

There is provided a process for preparing sorafenib or a salt thereof comprising the use of a compound of formula (A) wherein R′ is selected from the group consisting of hydrogen, —C(O)OA, —C(O)CX3, —C(O)NH2, —C(O)—NHOH or There is also provided intermediate compounds of general formula (A), N-methyl-4-(4-ureidophenoxy)picolinamide, 4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenylcarbamate derivative and N-methyl-4-(4-(2,2,2-trihaloacetamido)phenoxy)picolinamide, processes for their preparation and their use in the preparation of sorafenib.